New treatments for urinary tract infections caused by antibiotic-resistant bacteria
Official title: Novel therapeutics for treatment of catheter-associated UTI and depletion of the vaginal reservoir
Funded at Washington University · NIH-11014377 · Data updated 2026-11-12
This study is looking at new ways to help people with urinary tract infections caused by tough bacteria that don't respond to regular antibiotics, especially those linked to catheters, by using special antibodies to stop the bacteria from sticking to the catheters, which could lead to safer and better treatment options for you.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | February 10, 2023 |
| Project end | February 9, 2026 |
| Funding year | 2025 |
| Award (this year) | $53,974 |
| NIH project number | 5F30DK135390-03 |
| Project ID | NIH-11014377 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients who experience recurrent urinary tract infections, particularly those associated with catheter use.
✕Less likely to help
Patients with UTIs caused by non-resistant bacteria or those who do not use catheters may not benefit from this research.
What this research studies
This research focuses on developing new therapies to treat urinary tract infections (UTIs) caused by antibiotic-resistant bacteria, specifically targeting catheter-associated UTIs. The approach involves using monoclonal antibodies (mAbs) that can block the bacteria's ability to adhere to urinary catheters, which is a common cause of these infections. By preventing bacterial adherence, the goal is to reduce the need for antibiotics and combat the growing issue of antimicrobial resistance. Patients may benefit from safer and more effective treatment options that do not rely on traditional antibiotics.
Why it matters
Potential benefit: If successful, this research could provide patients with new treatment options that reduce reliance on antibiotics and combat antibiotic resistance.
How similar studies have gone: Previous research has shown success with monoclonal antibodies in treating other bacterial infections, indicating potential for this novel approach.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Timm, Morgan Rose Wilt — Washington University
- Study coordinator: Timm, Morgan Rose Wilt
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.